Genitourinary Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_15_3463 - Clinical Observation of Trimodalthermochemoradiotherapy for Locally Advanced Cervical Cancer

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Clinical Observation of Trimodalthermochemoradiotherapy for Locally Advanced Cervical Cancer
S. Ji1, Q. Chen1, and Y. Xu2; 1Department of Radiation Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, suzhou, China, 2Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, SuZhou, China

Purpose/Objective(s): To investigate the clinical effect and toxicity of trimodalthermochemoradiotherapy (RTHTCT) for locally advanced cervical cancer.

Materials/Methods: 66 patients with locally advanced cervical cancer were randomly assigned to the RTHTCT group (n=31) and simple chemo-radiotherapy (RTCT) group (n=35). All the patients received pelvic radiotherapy with IMRT plus intracavitary brachytherapy. The chemotherapy was cisplatin and hyperthermia was pelvic deep hyperthermia. At the end of treatment, the short-term efficacy and toxicity was evaluated in both groups.

Results: The complete remission rate (CR) and partial remission rate (PR) of group RTHTCT was significantly higher than that of RTCT group (93.5% vs. 74.3%, respectively). And the difference was statistical significance (p<0.05). The 1 year PFS comparison, the RTHTCT group and RTCT group was 87.1% and 74.3% respective. And there was no significant difference (P>0.05). There were no significant differences in hematological toxicity, upper gastrointestinal toxicity and urinary toxicity between the two groups, but the incidence of diarrhea in group RTHTCT was significantly lower than that in group RTCT, and there was statistical difference between the two groups (P<0.05).

Conclusion: Compared with RTCT alone, RTHTCT for locally advanced cervical cancer can improve the short-term effects, and reduce the diarrhea caused by chemoradiotherapy. Therefore, RTHTCT will bring clinical benefits to the patients, which is worthy of further study.

Author Disclosure: S. Ji: None. Q. Chen: None.

Send Email for Shengjun Ji


Assets

TU_15_3463 - Clinical Observation of Trimodalthermochemoradiotherapy for Locally Advanced Cervical Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Clinical Observation of Trimodalthermochemoradiotherapy for Locally Advanced Cervical Cancer